-
1Academic Journal
Authors: D. M. Kuchin, Ya. I. Kolesnik, H. G. Torgomyan, V. E. Zagainov, Д. М. Кучин, Я. И. Колесник, Г. Г. Торгомян, В. Е. Загайнов
Source: Malignant tumours; Том 11, № 1 (2021); 20-28 ; Злокачественные опухоли; Том 11, № 1 (2021); 20-28 ; 2587-6813 ; 2224-5057
Subject Terms: многофакторный анализ, ductal adenocarcinoma of the pancreas, overall survival, multivariate analysis, протоковая аденокарцинома поджелудочной железы, общая выживаемость
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/827/585; Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2018 // CA: A Cancer Journal for Clinicians. 2018. Vol. 68, № 1. P. 7–30.; Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries// CA: A Cancer Journal for Clinicians. 2018. Vol. 68, № 6. P. 394–424.; Allemani C. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD- 3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries// The Lancet. 2018. Vol. 391, № 10 125. P. 1023–1075.; Strobel O. et al. Optimizing the outcomes of pancreatic cancer surgery// Nature Reviews Clinical Oncology. Springer US, 2019. Vol. 16, № 1. P. 11–26.; Hackert T. et al. The TRIANGLE operation — radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study// Hpb. International Hepato-Pancreato-Biliary Association Inc., 2017. Vol. 19, № 11. P. 1001–1007.; Bilimoria K. Y. et al. Multimodality therapy for pancreatic cancer in the U. S.: Utilization, outcomes, and the effect of hospital volume// Cancer. 2007. Vol. 110, № 6. P. 1227–1234.; Altman A. M. et al. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival// Annals of Surgical Oncology. Springer International Publishing, 2019. Vol. 26, № 12. P. 4108–4116.; Huang L. et al. Resection of pancreatic cancer in Europe and USA: An international large-scale study highlighting large variations// Gut. 2019. Vol. 68, № 1. P. 130–139.; Luberice K. et al. Has survival improved following resection for pancreatic adenocarcinoma? // American Journal of Surgery. Elsevier Ltd, 2017. Vol. 214, № 2. P. 341–346.; Tian X. et al. Prognostic factors for disease-free survival in patients with pancreatic ductal adenocarcinoma after surgery// Journal of Pancreatology. 2019. Vol. 2, № 1. P. 22–27.; National Comprehensive Cancer Network. Pancreatic Adenocarcinoma Version 2. 2021 — February 25, 2021 URL: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.; Ducreux M. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up// Annals of Oncology. 2015. Vol. 26, № Supplement 5. P. v56 — v68.; Kuchin D.M. et al. Extensive gastropancreatoduodenal resections in the treatment of ductal carcinoma of the head of pancreas // Sovremennye Tehnologii v Medicine. 2012. Vol. 2012, № 3. P. 54–59.; Gillen S. et al. Preoperative / neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages// PLoS Medicine. 2010. Vol. 7, № 4. P. 1–15.; Versteijne E. et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer// British Journal of Surgery. 2018. Vol. 105, № 8. P. 946–958.; Tummers W. S. et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery// British Journal of Surgery. 2019. Vol. 106, № 8. P. 1055–1065.; Imamura T. et al. Prognostic role of the length of tumour — vein contact at the portal — superior mesenteric vein in patients having surgery for pancreatic cancer// British Journal of Surgery. 2019. Vol. 106, № 12. P. 1649–1656.; Ramacciato G. et al. Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients// Annals of Surgical Oncology. 2016. Vol. 23, № 6. P. 2028–2037.; Yu X. Z. et al. Benefit from synchronous portal-superior mesenteric vein resection during pancreaticoduodenectomy for cancer: A meta-analysis// European Journal of Surgical Oncology. 2014. Vol. 40, № 4. P. 371–378.; Prakash L. R. et al. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection// Journal of Gastrointestinal Surgery. Journal of Gastrointestinal Surgery, 2020. Vol. 24, № 2. P. 368–379.; Kim M. et al. Prediction and clinical implications of portal vein / superior mesenteric vein invasion in patients with resected pancreatic head cancer: the significance of preoperative CT parameters// Clinical Radiology. The Royal College of Radiologists, 2018. Vol. 73, № 6. P. 564–573.; Bergquist J. R. et al. Carbohydrate antigen 19–9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A national cancer database study// Journal of the American College of Surgeons. Elsevier Ltd, 2016. Vol. 223, № 1. P. 52–65.; Reni M. et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma// Annals of Oncology. 2017. Vol. 28, № 11. P. 2786–2792.; Haas M. et al. Prognostic value of CA19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy// Journal of Cancer Research and Clinical Oncology. 2013. Vol. 139, № 4. P. 681–689.; Goh S. K. et al. Serum carbohydrate antigen 19–9 in pancreatic adenocarcinoma: a mini review for surgeons// ANZ Journal of Surgery. 2017. Vol. 87, № 12. P. 987–992.; Kardosh A. et al. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study// Pancreas. 2018. Vol. 47, № 8. P. 958–966.; Tanaka M. et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer // British Journal of Surgery. 2019. Vol. 106, № 12. P. 1590–1601.; https://www.malignanttumors.org/jour/article/view/827
-
2Academic Journal
Authors: Tumanskyi, V. O., Kovalenko, I. S.
Source: Pathologia; Vol. 16 No. 1 (2019): Pathologia ; Патология; Том 16 № 1 (2019): Патологія ; Патологія; Том 16 № 1 (2019): Патологія ; 2310-1237 ; 2306-8027
Subject Terms: pancreatic ductal adenocarcinoma, pancreatic neoplasms, neoplastic stem cells, протоковая аденокарцинома поджелудочной железы, новообразования поджелудочной железы, неопластические стволовые клетки, протокова аденокарцинома підшлункової залози, новоутворення підшлункової залози, неопластичні стовбурові клітини
File Description: application/pdf
Relation: http://pat.zsmu.edu.ua/article/view/166476/167144; http://pat.zsmu.edu.ua/article/view/166476
Availability: http://pat.zsmu.edu.ua/article/view/166476
-
3Academic Journal
Authors: Kolesnikova, O. V.
Source: Современная гастроэнтерология; № 6 (2019); 59—67
Сучасна гастроентерологія; № 6 (2019); 59—67
Modern Gastroenterology; № 6 (2019); 59—67Subject Terms: цукровий діабет 3с типу, хронічний панкреатит, протокова аденокарцинома підшлункової залози, type 3c diabetes mellitus, chronic pancreatitis, pancreatic duct adenocarcinoma, сахарный диабет 3с типа, хронический панкреатит, протоковая аденокарцинома поджелудочной железы, 3. Good health
File Description: application/pdf
Access URL: http://sgastro.com.ua/article/view/MG-2019-6-59
-
4Academic Journal
Authors: L. A. Ruiatkina, D. S. Ruiatkin, Л. А. Руяткина, Д. С. Руяткин
Source: Meditsinskiy sovet = Medical Council; № 4 (2018); 28-35 ; Медицинский Совет; № 4 (2018); 28-35 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-4
Subject Terms: протоковая аденокарцинома поджелудочной железы, type 3c diabetes, chronic pancreatitis, ductal pancreatic adenocarcinoma, сахарный диабет типа 3с, хронический панкреатит
File Description: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2328/2311; Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev, 2012 May, 28(4): 338-42. doi:10.1002/dmrr.2260.; Malka D, Hammel P, Sauvanet A, Rufat P, O’Toole D, Bardet P, Belghiti J, Bernades P, Ruszniewski P, Lévy P. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology, 2000 Nov, 119(5): 1324-32.; Angelopoulos N, Dervenis C, Goula A, Rombopoulos G, Livadas S, Kaltsas D, Kaltzidou V, Tolis G. Endocrine pancreatic insufficiency in chronic pancreatitis. Pancreatology, 2005, 5(23): 122-31. doi:10.1159/000085264; Choudhuri G1, Lakshmi CP, Goel A. Pancreatic diabetes. Trop Gastroenterol, 2009 Apr-Jun, 30(2): 71-5.; Perusicová J. Diabetes mellitus in chronic pancreatitis. Vnitr Lek, 2004 May, 50(5): 375-8.; American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2006 Jan, 29(suppl 1): 43-48.; American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2011 Jan, 34(Suppl 1): 62–69.doi:10.2337/dc11-S062.; Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, Brand R, Frulloni L, Anderson MA, Whitcomb DC. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. PancreasFest Recommendation Conference Participants. Pancreatology, 2013, 13(4): 336-42. doi:10.1016/j.pan.2013.05.002.; Phil A Hart, Melena D Bellin, Dana K Andersen, David Bradley, Zobeida Cruz-Monserrate, Christopher E Forsmark, Mark O Goodarzi, Aida Habtezion, Murray Korc, Yogish C Kudva, Stephen J Pandol, Dhiraj Yadav, and Suresh T Chari, on behalf of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol, 2016 Nov, 1(3): 226–237. doi:10.1016/S2468-1253(16)30106-6.; Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol, 2013, 19(42): 7276-7281.; Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. Сахарный диабет, 2017, 20(1S): 1-112. doi:10.14341/DM20171S8; Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology, 2011, 11(3): 279-94. doi:10.1159/000329188.; Whitcomb DC, Frulloni L, Garg P, Greer JB, Schneider A, Yadav D, Shimosegawa T. Chronic pancreatitis: An international draft consensus proposal for a new mechanistic definition. Pancreatology, 2016 Mar-Apr, 16(2): 218-24. doi:10.1016/j.pan.2016.02.001.; Sheth SG, Conwell DL, Whitcomb DC, Alsante M, Anderson MA, Barkin J, Brand R, Cote GA, Freedman SD, Gelrud A, Gorelick F, Lee LS, Morgan K, Pandol S, Singh VK, Yadav D, Wilcox CM, Hart PA. Academic Pancreas Centers of Excellence: Guidance from a multidisciplinary chronic pancreatitis working group at PancreasFest. Pancreatology, 2017, 17(3): 419430. doi:10.1016/j.pan.2017.02.015.; Struyvenberg MR, Martin CR, Freedman SD. Practical guide to exocrine pancreatic insufficiency -Breaking the myths. BMC Med, 2017 Feb 10, 15(1): 29. doi:10.1186/s12916-017-0783-y.; Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez. Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol, 2017 Oct 21, 23(39): 7059-7076. doi:10.3748/wjg.v23.i39.7059.; Lew D, Afghani E, Pando S. Chronic Pancreatitis: Current Status and Challenges for Prevention and Treatment. Dig Dis Sci, 2017, 62(7): 1702– 1712. doi:10.1007/s10620-017-4602-2.; Gudipaty L and Rickels MR. Pancreatogenic (Type 3c) Diabetes. Pancreapedia: Exocrine Pancreas Knowledge Base. 2015. doi:10.3998/panc.2015.35.; Ребров А.П., Куницына М.А., Кашкина Е.И., Архангельская Е.Е. Панкреатогенный сахарный диабет: актуальные проблемы патогенеза и лечения (обзор). Саратовский научномедицинский журнал, 2012, 8(3): 862-867.; Niebisz-Cieślak AB and Karnafel W. Insulin sensitivity in chronic pancreatitis and features of insulin resistance syndrome. Pol Arch Med Wewn, 2010, 120: 255–263.; Brereton MF, Vergari E, Zhang Q, Clark A. Alpha-, Deltaand PP-cells: Are They the Architectural Cornerstones of Islet Structure and Co-ordination? J Histochem Cytochem, 2015 Aug, 63(8): 575–591. doi:10.1369/0022155415583535.; Прощина А.Е., Кривова Ю.С., Барабанов В.М., Савельев С.В. Иммуногистохимическое исследование наиболее крупных островков поджелудочной железы человека при старении и при сахарном диабете 1 и 2 типов, перспективы для трансплантации. Сахарный диабет, 2013, (4): 38–43.; Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis, aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol, 2010, 24: 349–358. doi:10.1016/j.bpg.2010.02.007.; Andersen DK, Andren-Sandberg A, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas, 2013, 42: 1227–1237. doi:10.1097/MPA.0b013e3182a9ad9d.; Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas, 2011, 40(3): 339–351. doi:10.1097/MPA.0b013e318209e05d; Eibl G, Cruz-Monserrate Z, Korc M, Petrov MS, Goodarzi MO, Fisher WE, Habtezion A, Lugea A, Pandol SJ, Hart PA, Andersen DK, Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. J Acad Nutr Diet, 2017 Sep 11, pii: S2212-2672(17)31087-0. doi:10.1016/j.jand.2017.07.005.; Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (Type 3c) Are we neglecting an important disease? Eur J Intern Med, 2013, 24: 203-206. PMID: 23375619.; Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR, Chari ST, Abbruzzese J L. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes, 2017 May, 66(5): 1103-1110. doi:10.2337/db16-1477.; Singer MV, Gyr K, Sarles H. Revised classification of pancreatitis. Gastroenterology, Report of the Second International Symposium on the classification of pancreatitis in Marseille, France. March 28–30, 1984, 1985: 683–685.; Yadav D, O’Connell M, Papachristou GI. Natural history following the first attack of acute pancreatitis. Am J Gastroenterol, 2012, 107: 1096– 1103. doi:10.1038/ajg.2012.126.; Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B, CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care, 2010 Dec, 33(12): 2697-708. doi:10.2337/dc10-1768.; Makuc J. Management of pancreatogenic diabetes: challenges and solutions. Diabetes Metab Syndr Obes, 2016, 9: 311–315. doi:10.2147/DMSO.S99701.; Irving HM, Samokhvalov AV, Rehm J. Alcohol as a risk factor for pancreatitis. A systematic review and meta-analysis. JOP, 2009, 10: 387–392.; Samokhvalov AV, Rehm J, Roerecke M. Alcohol consumption as a risk factor for acute and chronic pancreatitis: a systematic review and a series of meta-analyses. EBioMedicine, 2015, 2: 1996–2002. doi:10.1016/j.ebiom.2015.11.023.; Setiawan VW, Pandol SJ, Porcel J, et al. Prospective study of alcohol drinking, smoking, and pancreatitis: the multiethnic cohort. Pancreas, 2016, 45: 819–825.; Sikkens EC, Cahen DL, Koch AD, Braat H, Poley JW, Kuipers EJ, Bruno MJ. The prevalence of fatsoluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis. Pancreatology, 2013, 13: 238–242. DOI:10.1016/j.pan.2013.02.008.; Conlon KC, Duggan SN. Pancreatogenic Type 3c Diabetes: Underestimated, Underappreciated and Poorly Managed. Practical gastroenterology, 2017, serias#163. med.virginia.edu. https://med.virginia.edu/ginutrition/wp-content/ uploads/sites/199/2014/06/Parrish-May-17.pdf.; De-madaria E, Abad-gonzález A, Aparicio JR, et al. The Spanish Pancreatic Club’s recommendations for the diagnosis and treatment of chronic pancreatitis: part 2 (treatment). Pancreatology. 2013, 13: 18–28. doi: http://dx.doi.org/10.1016/j.pan.2012.11.310.; Bellin MD, Freeman ML, Gelrud A, et al. Total pancreatectomy and islet auto transplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology, 2014, 14: 27–35.; Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, Holst JJ, Krarup T. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab, 2007 Jan, 292(1): E324-30. DOI:10.1152/ajpendo.00059.2006.; Meier JJ, Giese A Diabetes associated with pancreatic diseases. Curr Opin Gastroenterol, 2015 Sep, 31(5): 400-6. doi:10.1097/MOG.0000000000000199.; Das S, Tripathy SK, Panda BP. Pancreatic Diabetes. Medicine Update, 2017. Section 18: Diabetes, 757-761. https: //issuu.com/urvitrivedi/docs/18_diabetes/1?ff=true.; Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B, American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009 Jan, 32(1): 193-203.; Руяткина Л.А., Руяткин Д.С. Многоплановые эффекты метформина у пациентов с сахарным диабетом 2 типа. Сахарный диабет, 2017, 20(3): 210-219. doi:10.14341/DM8676.; Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, Ren ZG, Jiang GL. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract, 2014 Oct, 106(1): 19-26. doi:10.1016/j.diabres.2014.04.007.; Dong YW, Shi YQ, He LW, Cui XY, Su PZ. Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget, 2017 May 26, 8(33): 55478-55488. doi:10.18632/oncotarget.18233.; Kowall B, Rathmann W, Kostev K. Are Sulfonylurea and Insulin Therapies Associated With a Larger Risk of Cancer Than Metformin Therapy? A Retrospective Database Analysis. Diabetes Care, 2015, 38(1): 59-65.; Li X, Li T, Liu Z, Gou S, Wang C The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep, 2017 Jul 19, 7(1): 5825. doi:10.1038/s41598-017-06207-x.; Yang JY, Kweon MN. The gut microbiota: a key regulator of metabolic diseases. BMB Rep, 2016 Oct, 49(10): 536-541.; Hur KY, Lee MS. New mechanisms of metformin action: Focusing on mitochondria and the gut. J Diabetes Investig, 2015, 6(6): 600–609. doi:10.1111/jdi.12328.; Jandhyala SM, Madhulika A, Deepika G, Rao GV, Reddy DN, Subramanyam C, Sasikala M, Talukdar R. Altered intestinal microbiota in patients with chronic pancreatitis: implications in diabetes and metabolic abnormalities. Scientific Reports, 2017, 3(7): 43640. doi:10.1038/srep43640.; Tilg H, Moschen AR. Microbiota and Diabetes: An Evolving Relationship. Gut, 2014, 63(9): 1513-21. doi:10.1136/gutjnl-2014-306928.; Sola D, Rossi L, Schianca GPC, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra G.P, Bartoli E, and Derosa G. Sulfonylureas and their use in clinical practice. Arch Med Sci, 2015 Aug 12, 11(4): 840–848. doi:10.5114/aoms.2015.53304.; Lee YH, Lee BW, Chun SW, Cha BS, Lee HC. Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure. Int J Clin Pract, 2011 Oct, 65(10): 1076-84. doi:10.1111/j.1742-1241.2011.02755.; Knop FK. Incretin hormones and beta cell function in chronic pancreatitis. Dan Med Bull, 2010 Jul, 57(7): B4163.; Iyer SN, Tanenberg RJ, Mendez CE, West RL, Drake AJ .Pancreatitis associated with incretinbased therapies. Diabetes Care, 2013 Apr, 36(4): e49. doi:10.2337/dc12-1987.; Egan A, et al. Pancreatic safety of incretinbased drugs – FDA and EMA assessment. N Engl J Med, 2014, 370: 794–6.; Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012, 367(4): 319-328.; Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report. Diabetes Care, 2010, 33(7): 1674-1685.
-
5Academic Journal
Source: Medical Visualization; № 4 (2016); 54-63 ; Медицинская визуализация; № 4 (2016); 54-63 ; 2408-9516 ; 1607-0763
Subject Terms: differential diagnosis, протоковая аденокарцинома поджелудочной железы, опухоли поджелудочной железы солидной структуры, дифференциальная диагностика, MDCT, pancreatic ductal adenocarcinoma, solid pancreatic lesion
File Description: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/297/298; Sachs T., Pratt W.B., Callery M.P., Vollmer C.M. Jr. The Incidental Asymptomatic Pancreatic Lesion: Nuisance or Threat? J. Gastrointest. Surg. 2009; 13 (3): 405-415.; Winter J.H., Cameron J.L., Lillemoe K.D. et al. Periampullary and pancreatic incidentaloma: A single institution’s experience with an increasingly common diagnosis. Ann. Surg. 2006; 243; 5: 673-683.; Lahat G., Ben Haim M., Nachmany I. et al. Pancreatic incidentalomas: high rate of potentially malignant tumors. J. Am. Coll. Surg. 2009; 209: 313-319.; Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J. Clin. 2001; 51 (1): 15-36.; Ries L.A.G., Kosary C.L., Hankey B.F. et al. SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999.; Jemal A., Siegel R., Ward E. et al. Cancer statistics 2009. CA Cancer J. Clin. 2009; 59: 225-249.; Паклина О.В., Кармазановский Г.Г., Сетдикова Г.Р. Патоморфологическая и лучевая диагностика хирургических заболеваний поджелудочной железы. М.: Видар-М, 2014. 188 с.; Egorov V.I., Petrov R.V., Solodinina E.N. et al. Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability. Wld J. Gastrointest. Surg. 2013; 5 (4): 83-96.; Осипова Н.Ю., Кармазановский Г.Г., Старков Ю.Г., Солодинина Е.Н. Магнитно-резонансная холангиопанкреатография и интраоперационные методы диагностики холедохолитиаза. Медицинская визуализация. 2004; 5: 29-35.; Белоусова Е.Л., Кармазановский Г.Г., Кубышкин В.А. и др. КТ-признаки, позволяющие определить оптимальную тактику лечения при нейроэндокринных опухолях поджелудочной железы. Медицинская визуализация. 2015; 5: 73-82.; Madan A.K., Weldon C.B., Long W.P. et al. Solid and papillary epithelial neoplasms of the pancreas. J. Surg. Oncol. 2004. 85:193-198.; Crippa S., Angelini C., Mussi C. et al. Surgical Treatment of Metastatic Tumors to the Pancreas: A Single Center Experience and Review of the Literature. Wld J. Surg. 2006; 30: 1536.; Hung J.H., Wang S.E., Shyr Y.M. et al. Resection for Secondary Malignancy of the Pancreas. Pancreas. 2012; 41 (1): 121-129.; Tanis P.J., van der Gaag N.A., Busch O.R. et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. Br. J. Surg. 2009; 96: 579-592.; Takahashi N., Fletcher J.G., Fidler J.L. et al. Dual-phase CT of autoimmune pancreatitis: a multireader study. Am. J. Roentgenol. 2008, 190: 280-286.; https://medvis.vidar.ru/jour/article/view/297
Availability: https://medvis.vidar.ru/jour/article/view/297
-
6Academic Journal
Authors: Чесноков, Михаил, Кустова, И., Шавочкина, Д., Кузнецова, А., Лазаревич, Н.
Subject Terms: ПРОТОКОВАЯ АДЕНОКАРЦИНОМА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ, HNF4α, ИЗОФОРМЫ, ЭКЗОГЕННАЯ ЭКСПРЕССИЯ, УРОВЕНЬ ДИФФЕРЕНЦИРОВКИ
File Description: text/html
-
7Academic Journal
Subject Terms: ПРОТОКОВАЯ АДЕНОКАРЦИНОМА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ, ГЕНЫ СУПРЕССОРЫ ОПУХОЛЕВОГО РОСТА, Р16, Р53, МЕТАСТИН
File Description: text/html
-
8Academic Journal
Source: Российский биотерапевтический журнал.
Subject Terms: 0301 basic medicine, 03 medical and health sciences, 0302 clinical medicine, ПРОТОКОВАЯ АДЕНОКАРЦИНОМА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ, HNF4α, ИЗОФОРМЫ, ЭКЗОГЕННАЯ ЭКСПРЕССИЯ, УРОВЕНЬ ДИФФЕРЕНЦИРОВКИ
File Description: text/html
-
9Academic Journal
Source: Вестник РОНЦ им. Н. Н. Блохина РАМН.
Subject Terms: ПРОТОКОВАЯ АДЕНОКАРЦИНОМА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ, ГЕНЫ СУПРЕССОРЫ ОПУХОЛЕВОГО РОСТА, Р16, Р53, МЕТАСТИН
File Description: text/html
